|
1
|
Adès L, Itzykson R and Fenaux P:
Myelodysplastic syndromes. Lancet. 383:2239–2252. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tefferi A and Vardiman JW: Myelodysplastic
syndromes. N Engl J Med. 361:1872–1885. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Alfinito F, Sica M, Luciano L, Della Pepa
R, Palladino C, Ferrara I, Giani U, Ruggiero G and Terrazzano G:
Immune dysregulation and dyserythropoiesis in the myelodysplastic
syndromes. Br J Haematol. 148:90–98. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kordasti SY, Ingram W, Hayden J, Darling
D, Barber L, Afzali B, Lombardi G, Wlodarski MW, Maciejewski JP,
Farzaneh F and Mufti GJ: CD4+CD25high Foxp3+ regulatory T cells in
myelodysplastic syndrome (MDS). Blood. 110:847–850. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Caligiuri MA: Human natural killer cells.
Blood. 112:461–469. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hejazi M, Manser AR, Frobel J, Kündgen A,
Zhao X, Schönberg K, Germing U, Haas R, Gattermann N and Uhrberg M:
Impaired cytotoxicity associated with defective natural killer cell
differentiation in myelodysplastic syndromes. Haematologica.
100:643–652. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chamuleau ME, Westers TM, van Dreunen L,
Groenland J, Zevenbergen A, Eeltink CM, Ossenkoppele GJ and van de
Loosdrecht AA: Immune mediated autologous cytotoxicity against
hematopoietic precursor cells in patients with myelodysplastic
syndrome. Haematologica. 94:496–506. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Epling-Burnette PK, Bai F, Painter JS,
Rollison DE, Salih HR, Krusch M, Zou J, Ku E, Zhong B, Boulware D,
et al: Reduced natural killer (NK) function associated with
high-risk myelodysplastic syndrome (MDS) and reduced expression of
activating NK receptors. Blood. 109:4816–4824. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vardiman JW, Thiele J, Arber DA, Brunning
RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM,
Hellström-Lindberg E, Tefferi A and Bloomfield CD: The 2008
revision of the World Health Organization (WHO) classification of
myeloid neoplasms and acute leukemia: Rationale and important
changes. Blood. 114:937–951. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Greenberg P, Cox C, LeBeau MM, Fenaux P,
Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, et al:
International scoring system for evaluating prognosis in
myelodysplastic syndromes. Blood. 89:2079–2088. 1997.PubMed/NCBI
|
|
11
|
Kogure T, Fujinaga H, Niizawa A, Hai LX,
Shimada Y, Ochiai H and Terasawa K: Killer-cell inhibitory
receptors, CD158a/b, are upregulated by interleukin-2, but not
interferon-gamma or interleukin-4. Mediators Inflamm. 8:313–318.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
El-Sherbiny YM, Meade JL, Holmes TD,
McGonagle D, Mackie SL, Morgan AW, Cook G, Feyler S, Richards SJ,
Davies FE, et al: The requirement for DNAM-1, NKG2D and NKp46 in
the natural killer cell-mediated killing of myeloma cells. Cancer
Res. 67:8444–8449. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Baychelier F, Sennepin A, Ermonval M,
Dorgham K, Debré P and Vieillard V: Identification of a cellular
ligand for the natural cytotoxicity receptor NKp44. Blood.
122:2935–2942. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shibuya A, Campbell D, Hannum C, Yssel H,
Franz-Bacon K, McClanahan T, Kitamura T, Nicholl J, Sutherland GR,
Lanier LL and Phillips JH: DNAM-1, a novel adhesion molecule
involved in the cytolytic function of t lymphocytes. Immunity.
4:573–581. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Carlsten M, Baumann BC, Simonsson M,
Jädersten M, Forsblom AM, Hammarstedt C, Bryceson YT, Ljunggren HG,
Hellström-Lindberg E and Malmberg KJ: Reduced DNAM-1 expression on
bone marrow NK cells associated with impaired killing of CD34+
blasts in myelodysplastic syndrome. Leukemia. 24:1607–1616. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schlegel P, Ditthard K, Lang P, Mezger M,
Michaelis S, Handgretinger R and Pfeiffer M: NKG2D signaling leads
to NK cell mediated lysis of childhood AML. J Immunol Res.
2015:4731752015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Konjević G, Mirjacić Martinović K, Jurisić
V, Babović N and Spuzić I: Biomarkers of suppressed natural killer
(NK) cell function in metastatic melanoma: decreased NKG2D and
increased CD158a receptors on CD3-CD16+ NK cells. Biomarkers.
14:258–270. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Battella S, Cox MC, Santoni A and Palmieri
G: Natural killer (NK) cells and anti-tumor therapeutic mAb:
Unexplored interactions. J Leukoc Biol. 99:87–96. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ebert LM, Meuter S and Moser B: Homing and
function of human skin gammadelta T cells and NK cells: Relevance
for tumor surveillance. J Immunol. 176:4331–4336. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Aggarwal N, Swerdlow SH, TenEyck SP,
Boyiadzis M and Felgar RE: Natural killer cell (NK) subsets and
NK-like T-cell populations in acute myeloid leukemias and
myelodysplastic syndromes. Cytometry B Clin Cytom. 90:349–357.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cooper MA, Fehniger TA, Turner SC, Chen
KS, Ghaheri BA, Ghayur T, Carson WE and Caligiuri MA: Human natural
killer cells: A unique innate immunoregulatory role for the CD56
(bright) subset. Blood. 97:3146–3151. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bryceson YT, March ME, Ljunggren HG and
Long EO: Activation, coactivation, and costimulation of resting
human natural killer cells. Immunol Rev. 214:73–91. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vivier E, Nunès JA and Vély F: Natural
killer cell signaling pathways. Science. 306:1517–1519. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vivier E, Raulet DH, Moretta A, Caligiuri
MA, Zitvogel L, Lanier LL, Yokoyama WM and Ugolini S: Innate or
adaptive immunity? The example of natural killer cells. Science.
331:44–49. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bachanova V and Miller JS: NK cells in
therapy of cancer. Crit Rev Oncog. 19:133–141. 2014. View Article : Google Scholar : PubMed/NCBI
|
